Does the platelet-activated clotting test (HemoSTATUS) predict blood loss and platelet dysfunction associated with cardiopulmonary bypass?
Platelet dysfunction is a major cause of bleeding after cardiopulmonary bypass (CPB). No timely, simple, point-of-care determinant of platelet function is available for clinical use. Adding platelet-activating factor to conventional activated clotting time methods (platelet-activated clotting test [PACT]) (HemoSTATUS; Medtronic, Inc., Parker, CO) produces rapid results (<3 min) and may yield a measure of platelet responsiveness and whole blood procoagulant activity. Blood samples were drawn for PACT, platelet count, prothrombin time, activated partial thromboplastin time, and thromboelastogram (TEG) from 200 patients undergoing cardiac surgery. The PACT significantly decreased from the baseline to postprotamine time interval (P < 0.001). The PACT correlated with 4-h mediastinal blood loss (r = -0.30, P = 0.014). The TEG maximum amplitude also correlated with 4-h mediastinal blood loss (r = -0.32, P = 0.003). The PACT had a sensitivity and specificity comparable to routine laboratory co
Related Questions
- Does the Platelet-Activated Clotting Test (HemoSTATUSR) Predict Blood Loss and Platelet Dysfunction Associated with Cardiopulmonary Bypass?.
- Does the platelet-activated clotting test (HemoSTATUS) predict blood loss and platelet dysfunction associated with cardiopulmonary bypass?
- Are ultrasonographic myoma characteristics associated with blood loss at delivery?
